Myeloma
165
24
34
77
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
37 trials with published results (22%)
Research Maturity
77 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.9%
23 terminated out of 165 trials
77.0%
-9.6% vs benchmark
5%
8 trials in Phase 3/4
48%
37 of 77 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 77 completed trials
Clinical Trials (165)
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Rutgers University Study of the Genetics of Blood Cancers
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
REal World MAIA UK OutcomEs
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
Understanding Patterns of Fatigue in Health and Disease
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
Evaluation of Skin Tests in Biotherapy Allergies
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Pilot Imaging Study of Leukemia
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy